Took a position in ABCL as a counter to my other Digital Biology/AI Augmented Biotech, ABSI. ABSI designs monoclonal antibodies against zero-prior epitope while ABCL generates antibodies against known epitopes. What makes ABCL special is that it is breaking out TA wish with solid FA. It has zero debt with a fortress balance sheet and stock that is trading NEAR BOOK VALUE bc it was beaten down due to a prolonged IP lawsuit which was just recently settled in the company's favor (derisking it). Furthermore, it has $1.9m in market-bought insider transactions with nondilutive optionality with some big name partners include LLY. 🍌(CryptoCondom)